# A Clinical Study to Enable Process Validation of Commercial Grade OTL-101

> **NCT04140539** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **University of California, Los Angeles**

## Conditions studied

- Severe Combined Immunodeficiency Due to ADA Deficiency

## Interventions

- **BIOLOGICAL:** OTL-101

## Key facts

- **NCT ID:** NCT04140539
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-15
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment on hold for business reasons. Study will not be performed.
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140539, "A Clinical Study to Enable Process Validation of Commercial Grade OTL-101". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT04140539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*